Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Chemoradiotherapy for Ultra-low Rectal Cancer
NCT07132463Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Aug 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tislelizumab in rectal cancer, sponsored by Fudan University. Started Aug 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07132463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07132463.